Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25396358 | 1.00 | KDR (0.40) | KDRCNR2CLK1CNR1CDC7 | |
| SCHEMBL5989853 | 0.80 | ALDH1A1 (0.46) | KDRCNR2KMT2AALDH1A1MEN1 | |
| SCHEMBL25395944 | 0.78 | PPARG (0.39) | ALDH1A1MAPT | |
| SCHEMBL25395939 | 0.78 | PPARG (0.39) | ALDH1A1MAPT | |
| SCHEMBL5990018 | 0.72 | CDC7 (0.47) | CLK1CDC7KMT2AACHEALDH1A1 | |
| SCHEMBL10967877 | 0.72 | ALDH1A1 (0.46) | CDC7KMT2AACHEALDH1A1MEN1 | |
| SCHEMBL8605149 | 0.70 | GAA (0.56) | ALDH1A1MAPT | |
| SCHEMBL31513055 | 0.69 | HTT (0.45) | KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL6196774 | 0.69 | MEN1 (0.44) | CDC7KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL30573352 | 0.69 | PARG (0.47) | CDC7KMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4493562-A1 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | KDR 2598/4885CNR2 1940/4885CLK1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.